共 50 条
Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution
被引:0
|作者:
Liu, Tao
[1
,2
]
Hogan, Joseph W.
[1
,2
,3
]
Daniels, Michael J.
[4
,5
]
Coetzer, Mia
[6
]
Xu, Yizhen
[1
,2
]
Bove, Gerald
[1
,2
]
DeLong, Allison K.
[1
,2
]
Ledingham, Lauren
[6
]
Orido, Millicent
[3
]
Diero, Lameck
[3
,7
]
Kantor, Rami
[6
]
机构:
[1] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA
[2] Brown Univ, Sch Publ Hlth, Ctr Stat Sci, Providence, RI 02912 USA
[3] Acad Model Providing Access Healthcare AMPATH, Eldoret, Kenya
[4] Univ Texas Austin, Dept Stat & Data Sci, Austin, TX 78712 USA
[5] Univ Texas Austin, Dept Integrat Biol, Austin, TX 78712 USA
[6] Brown Univ, Alpert Med Sch, Div Infect Dis, Providence, RI 02912 USA
[7] Moi Univ, Coll Hlth Sci, Sch Med, Dept Med, Eldoret, Kenya
基金:
美国国家卫生研究院;
关键词:
antiretroviral monitoring;
viral load pooling;
viral load;
virological failure;
ANTIRETROVIRAL TREATMENT FAILURE;
DEFECTIVE MEMBERS;
POOLING SERA;
INFECTION;
RNA;
CD4;
DISEASE;
SPECIMENS;
ADHERENCE;
ACCURACY;
D O I:
10.1097/QAI.0000000000001424
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Objective: Improve pooled viral load (VL) testing to increase HIV treatment monitoring capacity, particularly relevant for resource-limited settings. Design: We developed marker-assisted mini-pooling with algorithm (mMPA), a new VL pooling deconvolution strategy that uses information from low-cost, routinely collected clinical markers to determine an efficient order of sequential individual VL testing and dictates when the sequential testing can be stopped. Methods: We simulated the use of pooled testing to ascertain virological failure status on 918 participants from 3 studies conducted at the Academic Model Providing Access to Healthcare in Eldoret, Kenya, and estimated the number of assays needed when using mMPA and other pooling methods. We also evaluated the impact of practical factors, such as specific markers used, prevalence of virological failure, pool size, VL measurement error, and assay detection cutoffs on mMPA, other pooling methods, and single testing. Results: Using CD4 count as a marker to assist deconvolution, mMPA significantly reduces the number of VL assays by 52% [confidence interval (CI): 48% to 57%], 40% (CI: 38% to 42%), and 19% (CI: 15% to 22%) compared with individual testing, simple mini-pooling, and mini-pooling with algorithm, respectively. mMPA has higher sensitivity and negative/positive predictive values than mini-pooling with algorithm, and comparable high specificity. Further improvement is achieved with additional clinical markers, such as age and time on therapy, with or without CD4 values. mMPA performance depends on prevalence of virological failure and pool size but is insensitive to VL measurement error and VL assay detection cutoffs. Conclusions: mMPA can substantially increase the capacity of VL monitoring.
引用
收藏
页码:580 / 587
页数:8
相关论文